Skip to main content
Premium Trial:

Request an Annual Quote

Evonetix, Imec Collaborate on Silicon Chip Manufacturing for DNA Synthesis

NEW YORK – Evonetix announced Monday a partnership with Belgium-based nanoelectronics firm Imec to increase the scale of production of Evonetix's silicon chips for use in DNA synthesis.

Under the agreement, the firms will work together to scale up manufacturing of Evonetix's microelectromechanical systems-based chips on 8-inch silicon wafers.

"With the support of Imec, a world-renowned leader in microchip technology, we will be able to optimize our highly parallel desktop platform for commercial supply," Evonetix CTO Matthew Hayes said in a statement.

Financial and other terms of the agreement were not disclosed.

UK-based Evonetix is developing a desktop device for DNA synthesis. In 2018, it partnered with LioniX International to develop a bespoke silicon array to enable high-throughput production of gene-length DNA. Evonetix also closed a $12.3 million funding round in 2018 and launched a £1.3 million ($1.7 million) project in partnership with Durham University to develop its technology.

"We have extensive practical knowledge of chip design and technology, which we use to help develop innovative tools for the life sciences and pharma R&D," Peter Peumans, Imec VP of life science technologies, said in a statement. "Evonetix has developed an innovative approach that integrates physics and biology to enable the production of high-fidelity long DNA in a highly parallel fashion. We are eager to contribute to their success using our nanotechnology capabilities."

In March 2019, Imec announced it is working on solid-state nanopore technologies for single-molecule sensing and DNA sequencing applications.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.